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Abstract
Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) microspheres containing flurbiprofen were prepared by an oil-in-water
emulsion solvent evaporation method, in order to develop a particulate drug delivery system for localized administration.
A response surface method (RSM) using a central composite design was employed to evaluate the effect of the poly(vinyl alcohol)
(PVA) (%, w/v) concentration in the aqueous phase and the PHBV concentration in the organic phase (%, w/v) on some of the
resulting microspheres properties. The response variables were the encapsulation efficiency (EE), the mean particle size, the width
of particle size distribution (expressed by the SPAN value) and the required time for the in vitro release of 50% of the
encapsulated drug (t50%). Second-order polynomial and linear equations were fitted to experimental data and were also used to
interpret the results. Results indicated that the concentration of the stabilizer (PVA) showed a highly negative effect on the EE
probably due to the increased drug solubility in the aqueous phase as a result of the higher PVA concentrations. Particle diameter
mean size increased with the increased polymer concentration while the width of the particle size distribution was found
to decrease with the increase of the stabilizer agent. Finally, results indicated that none of the investigated variables presented
a significant effect on the t50% values.
Keywords: Poly(3-hydroxybutyrate-co-3-hydroxyvalerate), flurbiprofen, microspheres, central composite design
Introduction
The preparation of microcapsules and microspheres of
biodegradable polymers as vehicles for the controlled
release of bioactive agents (i.e. drugs, proteins, peptides,
genetic material) has been the focus of much investiga-
tion and has been a growing research field in
recent years (Freiberg and Zhu 2004). Usually, the
main goal in the design of a polymeric nano/micro-
particulated system for delivering a specific drug is to
achieve a controlled release rate of the drug into the
desired specific site of action and at therapeutic optimal
levels. This can be done by tailoring several nano/
microparticles properties such as particle size and
particle size distribution, bulk and surface morphology,
drug loading capacity and drug load homogeneity,
kinetics of drug release, etc. These characteristics will
always be defined by the physical and chemical
properties of all involved species (polymers, drugs,
solvents, surfactants), by the method employed to
prepare the loaded particles and by the several
operational parameters of the manufacture process.
Among the large number of polymers and
copolymers tested for the preparation of biodegradable
microspheres, poly(lactic acid) (PLA) and its copolymer
poly(lactic acid-co-glycolic acid) (PLGA) are the most
extensively investigated due, essentially, to their excel-
lent biocompatibility and biodegradability properties
(Hyon 2000). More recently, polyhydroxyalkanoates
(PHAs), a class of biodegradable and biocompatible
polyesters of biological origin, started receiving
considerable attention as a biomaterial presenting
great potential for biomedical and pharmaceutical
applications (Pouton and Akhtar 1996). The most
common representatives of these type of biomaterials
are those usually containing hydroxyalkanoic acid
monomeric units, like poly(3-hydroxybutyric acid),
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PHB, and also a related copolymer, poly(3-hydroxybu-
tyrate-co-3-hydroxyvalerate), PHBV. Their use as tissue
scaffolds and as drug delivery vehicles have been
reported (Pouton and Akhtar 1996, Williams et al.
1999, Khang et al. 2001, Baran et al. 2002, Chen and
Davis 2002). Their in vivo performances are also being
currently investigated (Qu et al. 2006).
The oil-in-water (O/W) emulsion solvent evaporation
method is a common procedure to microencapsulate
water-insoluble drugs within water-insoluble polymers
(O’Donnell and McGinity 1997, Freitas et al. 2005).
Usually, this process involves the dissolution of
a hydrophobic drug in a solution of a volatile organic
solvent and a water-insoluble polymer. Then, the
emulsification of the polymerþ drug containing organic
phase is done within an aqueous phase and the organic
solvent is removed (using heat, freeze-drying or
vacuum), resulting in the precipitation of the polymeric
material into drug-loaded microspheres. Several process
variables will influence the final characteristics of the
microspheres prepared by this method, like the aqueous
solubility of the drug, the type and amount of
used surfactant, the nature of the oil/organic phase,
the oil-to-water phase ratio, the drug-to-polymer
phase ratio, the stirring speed and the operational
temperature (O’Donnell and McGinity 1997).
The objective of this work is to make and character-
ize drug-loaded PHBV microsphere prepared by the
oil-in-water (O/W) emulsion solvent evaporation
method. To evaluate the influence of some process
variables in final physical-chemical properties of the
obtained microspheres, a response surface experimental
design was planned and implemented. Two variables
were investigated: the concentration in the aqueous
phase of the emulsion stabilizer, poly(vinyl alcohol)
(PVA), and the PHBV concentration in the organic
phase. The experimental design, classified as a surface
response central composite design (Montgomery 2001),
was chosen since it allows the understanding of
the influence of the above referred two combined
factors on the microspheres properties with a minimum
of experimental assays. In particular, it is possible to
estimate second-order polynomial equations and to
map the response over the experimental domain in
order to determine optimum conditions for the
formulations.
Flurbiprofen was chosen as the model drug to
encapsulate. This compound is a potent non-steroidal
anti-inflammatory drug (NSAID) used in the treatment
and control of the signs and symptoms of several
inflammatory chronic processes, like rheumatoid
arthritis (Lu et al. 2007) and periodontal diseases
(Samati et al. 2006). It is also commonly used in
ophthalmology to reduce and prevent post-operative
inflammations (Vega et al. 2006, Pignatello et al. 2002).
Like other NSAIDs, the oral administration of this
drug is limited because of the documented toxicity at
the gastrointestinal level (Cryer and Feldman 1998).
To prepare more safe and efficient formulations of this
drug, several authors have encapsulated it in
biodegradable microspheres and nanospheres, intended
as possible localized delivery systems. Examples are the
work of Samati et al. (2006) that investigated the
encapsulation of the salt form of flubiprofen in
copolymers of PLGA as a drug delivery system for
the periodontal pocked. Vega et al. (2006) also
investigated the encapsulation of flurbiprofen in
PLGA nanospheres as a possible ocular drug delivery
system, while Lu et al. (2007) recently prepared
flurbiprofen gelatine microspheres for intra-articular
administration in the joint cavity.
Experimental
Experimental design
A central composite experimental design was used to
study the effects of two formulation factors on some of
the microspheres properties. The two investigated
factors (independent variables) were the stabilizer
agent concentration in the aqueous phase (%w/v
PVA) and the polymer concentration in the organic
phase (%w/v PHBV).
The analysed dependent variables were the encapsu-
lation efficiency (EE), the mean particle size, the width
of particle size distribution (expressed by the SPAN
value) and the required time for the in vitro release of
50% of the encapsulated drug (t50%). All the remaining
factors, such as the oil-to-water phase ratio, drug-
to-polymer ratio, stirring speed and temperature, were
kept constant. Each independent variable was studied
at five levels, with an -value of 1.414 and three
replicates for the centre point. Table I shows the coded
levels and actual values of the investigated factors.
Design-Expert (Version 6.0.10, Stat-Ease Inc,
Minneapolis, USA) was used for the generation of the
experimental design, modelling and statistical
evaluation.
Materials
Poly(hydroxybutyrate-co-hydroxyvalerate), PHBV (6%
mol HV, Mw¼ 223 kDa), was purchased from PHB
Industrial SA (Brazil). Flurbiprofen (purity>98%)
and poly(vinyl alcohol), PVA (80% hydrolysed, av.
Mw 13–23 kDa), were supplied by Sigma-Aldrich
Table I. Coded and actual values of the investigated factors.
Levels
Factors 1.414 1 0 1 1.414
X1: PVA concentration (%, w/v) 0.38 1.00 2.50 4.00 4.60
X2: PHBV concentration (%, w/v) 0.88 1.50 3.00 4.50 5.12
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(St. Louis, USA). Chloroform was obtained from Jose´
A. Vaz Pereira (Lisbon, Portugal).
Preparation of microspheres
Flurbiprofen-containing PHBV microspheres were
prepared by the traditional oil-in water (O/W) emulsion
solvent evaporation technique. To a solution of PHBV
in chloroform (used compositions: 0.88, 1.50, 3.00, 4.50
and 5.12%, gmL1), was added and dissolved a
determined amount of flurbiprofen (3 g flurbiprofen/
10 g PHBV). After, 10mL of the organic solution was
dropped slowly into a mechanical stirred glass reactor,
charged with 100mL of a PVA solution (used
compositions: 0.38, 1.00, 2.50, 4.00 and 4.60%,
gmL1) to form the O/W emulsion. The reactor was
immersed in a water-bath at a constant and controlled
temperature (30C). The obtained O/W emulsion was
continuously stirred, at 1400 rpm and for 4 h, to permit
the evaporation of the organic solvent. The resulting
microspheres were collected by centrifugation, at
3000 rpm, and then washed three times with deionised
water and dried in a vacuum oven (at 40C). The dried
microspheres were stored in a dessicator until
further use.
Experimental drug loading and encapsulation
efficiency
The microspheres drug content was determined by UV
spectrophotometry. A weighed amount (10mg) of
drug-loaded PHBV microspheres was dissolved in 1mL
of chloroform, followed by the addition of 9mL of
methanol to precipitate the polymer. The resulting
suspension was centrifuged and the supernatant was
filtrated and analysed in a UV spectrophotometer
(Jasco, model V-550) at 247 nm. A calibration curve
was generated, at the same wavelength, using
pre-prepared standard solutions of flurbiprofen in
chloroform/methanol mixtures (1 : 9). Triplicate mea-
sures were performed for each batch. Experimental
drug loading was calculated as follows:
Experimental drug loading
¼ weight of detected drug
weight of drug loaded microspheres
ð1Þ
Theoretical drug loading was kept constant to all
batches (23%) and was defined as:
Theoretical drug loading
¼ weight of added drug
weight of added drugþ weight of added polymer
ð2Þ
Encapsulation efficiency (EE, %) was expressed as the
ratio between the experimental drug and the theoretical
drug loadings.
Determination of flurbiprofen solubility in PVA
aqueous solutions
The solubility of flurbiprofen in 0.50% (w/v) and
4.50% PVA aqueous solutions was measured at 25C.
A known amount of flurbiprofen was added to 20mL
of PVA solutions, in closed flasks, and left to dissolve
during 5 days under magnetic stirring. Aliquots of the
saturated solutions were then drawn, conveniently
diluted and analysed for absorbance intensity in a UV
spectrophotometer (Jasco, model V-550) at 247 nm.
Flurbiprofen content was calculated using standard
calibration curves obtained with aqueous solutions with
the same PVA concentrations. Triplicate flurbiprofen
saturated PVA solutions were prepared for each
concentration.
Particle size distribution
Microspheres particle size and particle size distribution
were measured by a laser light scattering analyser
(Coulter, model LS130). A suitable amount of dried
microspheres, from each formulation was suspended in
deionized water and sonicated before measurement.
The resulting homogenized suspension was then
analysed for the volume mean diameter and particle
size distribution. Frauenhofer’s method was used to
calculate the particle size distributions. The width of
these distributions was expressed in terms of SPAN
factor, defined as:
SPAN ¼ d90  d10
d50
ð3Þ
In this equation, d10, d50 and d90 represent the
diameter value for which a given percentage of particles
is smaller than that size. Therefore, the SPAN value
indicates the spread of the particle size distribution
and small SPAN values are indicative of narrow
particle size distributions.
Surface morphology
Microspheres particle shape and particle surface
morphologies were analysed by scanning electron
microscopy (SEM). Microspheres were placed on
double-sided graphite tape attached onto a metal
surface and coated with copper on a sputtering
coater. Observations were performed at 20 kV with a
JSM-5310 (JEOL, Japan) scanning electron
microscope.
In vitro drug release studies
A dialysis method was used for the in vitro kinetics of
drug release studies. A certain amount of drug-loaded
microspheres, containing 1mg of flurbiprofen,
were weighted and added to dialysis bags (with a cut-
off of 12–14 kDa). Bags were filled with 20mL of saline
solution (3.5 g L1 Naþ, 5.4 g L1 Cl, pH 6.0) and
172 P. A. Coimbra et al.
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introduced in beaker flasks filled with 50mL of saline
solution. The release medium was stirred at 120 rpm at
a constant temperature (37C). Then, 1.6mL of
solution was drawn out at pre-determined time intervals
and the release medium was replenished with the same
volume of fresh saline solution. Flurbiprofen content
was determined by UV spectrophotometry at 247 nm.
For comparison, the dissolution of 1mg of free drug
and a physical mixture of drug and blank PHBV
microspheres was also performed at the same
conditions.
Thermal analysis
Thermal analyses of the microspheres and of the pure
drug were performed with a modulated differential
scanning calorimeter (TA Instruments, model Q100
MDSC). Samples of 2.5–12mg were placed into
aluminium containers and heated, at a constant rate
(5Cmin1), from 20 to 200C under a nitrogen
atmosphere.
Results and discussion
The use of a response surface method experimental
design permits the construction of second-order poly-
nomial models that can describe quantitatively the
linear, quadratic and interaction effects of the selected
factors on the studied response variables. For two
factors, the general model corresponds to the following
equation:
Y ¼ b0 þ b1X1 þ b2X2 þ b11X21 þ b22X22 þ b1X1X2 ð4Þ
In this equation, X1 and X2 are the independent
variables (factors) and Y is the investigated dependent
variable (response). Also, b0 represents the arithmetic
average of all quantitative outcomes of all the runs, b1
and b2 are related with the independent variables effect
on the response, b11 and b22 are two quadratic
relationships and b12 represents the interaction effect
between the two variables. A coefficient with a positive
sign signifies a synergistic effect, whereas a negative sign
stands for an antagonistic effect.
As referred, the independent variables studied in
this work were the PVA concentration in the aqueous
phase (X1) and the PHBV concentration in the
organic phase (X2), while the analysed response
variables were the encapsulation efficiency (Y1),
the mean particle size of the microspheres (Y2), the
width of the particle size distribution, expressed by
the SPAN value (Y3) and the time for the in vitro
release of 50% of the encapsulated drug (Y4). Design-
Expert software was the employed tool to analyse
the response variables and to generate the polynomial
models. Model simplification was carried out by
eliminating insignificant parameters (those parameters
with the higher p-values) in the polynomial equations
resulting from multiple regression analysis.
The obtained models to describe the dependent
variables were selected taking in account their
statistical significance (p<0.01). The experimental
runs of the implemented central composite design and
the responses of the investigated dependent variables
are listed in Table II.
Encapsulation efficiency
The values for the flurbiprofen in PHBV microspheres
encapsulation efficiency (EE) (Y1, Table II)
ranged between 20.9 0.7% (4% PVA, 1.5% PHBV)
and 71.1 2.1% (0.38% PVA, 3% PHBV), which
corresponds to experimental drug loadings of
4.8 0.2% and 16.4 0.5%, respectively. The obtained
values for this response were fitted by a quadratic
model using the least squares method (r2¼ 0.9331):
EEð%Þ ¼ 56:6 24:5PVAþ 7:9PHBVþ 2:4PVA 2
 0:8PHBV 2 þ 1:9PVA PHBV ð5Þ
The obtained regression coefficients show that EE is
significantly influenced by the two investigated factors
but in opposite ways (p<0.01). In addition, the
positive quadratic effect of PVA appears to be
Table II. Experimental runs and responses of the central composite experimental design.
Batch
X1 PVA
(%, w/v)
X2 PHBV
(%, w/v) Y1 EE (%)
Y2 Mean
size (mm) Y3 SPAN Y4 t50% (min)
1 2.5 3 40.6 1.4 8.7 2.2 105
2 0.38 3 71.1 2.1 7.0 3.7 108
3 4.62 3 29.6 1.9 10.4 1.8 123
4 2.5 0.88 22.0 1.0 4.6 1.7 112
5 4 1.5 20.9 0.7 5.4 2.2 105
6 1 1.5 42.5 1.1 9.9 3.5 145
7 4 4.5 56.0 1.3 8.5 1.8 155
8 1 4.5 60.4 3.8 11.3 4.6 220
9 2.5 3 41.9 1.9 12.0 1.6 112
10 2.5 5.12 50.2 0.5 19.2 2.0 110
11 2.5 3 39.5 0.7 10.3 1.8 112
*Centre points.
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statistically significant (p<0.1). On the other hand, the
quadratic effect of PHBV and the interaction effect
between variables is not statistically different from zero
(p>0.1), being kept in the model only to support the
hierarchy of the polynomial equation. The relationship
between EE and the independent variables is further
illustrated whit a response surface plot, displayed in
Figure 1.
The fitted model shows that the stabilizer’s concen-
tration in the aqueous phase (% PVA) is the factor that
has a higher impact in the EE, with a large negative
effect. In the literature, the reported effect of PVA
concentration in the EE of drug-loaded microspheres
prepared by the O/W solvent evaporation method
varies according to the drug/polymer systems investi-
gated. While some authors report an increase of EE
with the increase of the stabilizer concentration
(Samati et al. 2006) or report that this variable
doesn’t statistically influence the obtained values of
the EE (Bolourtchian et al. 2005), other studies, like the
present one, conclude that the increase of the stabilizer
concentration has a negative effect in the EE (Lai and
Tsiang 2004, Fu et al. 2005).
Considering that, in the solvent evaporation
method, the drug entrapment efficiency reflects the
partition of the drug between the disperse organic
phase and the continuous aqueous phase during
microspheres solidification and precipitation, the
decrease of EE with the increase in PVA concentra-
tion can be explained by the resulting solubility
enhancement of flurbiprofen in the aqueous
phase due to the presence of these increasing amounts
of PVA. In fact, the solubility measurements
of flurbiprofen in PVA aqueous solutions showed
a significantly solubility increase from
0.173 0.010mgmL1 in a 0.5% PVA solution, up
to 0.336 0.006mgmL1 in a 4.5% PVA solution.
Compared with the solubility of flurbiprofen in pure
water, 0.01mgmL1 (Park and Kim 1999), the
solubility of flurbiprofen in the presence of PVA is
remarkably enhanced (more than 10-times).
This phenomenon, the increase of solubility of
poorly water-soluble drugs in surfactant solutions
(micellization), is well reported in literature (Li and
Zhao 2003, Yiyun and Jiepin 2005, Park and Choi
2006), being used as a strategy to improve the
bioavailability of water insoluble drugs, in particular
NSAIDs.
The other studied factor, the polymer concentration
in the organic phase (% PHBV), has a significantly
positive contribution to EE. The increase of EE
with the increase of polymer concentration is well
established in the literature and is explained by the
viscosity increase of the disperse phase, which restricts
the drug migration to the continuous phase
(Freitas et al. 2005).
Particle size distribution
For all the experimental batches, unimodal size
distributions were obtained, with mean particle sizes
ranging from 4.6mm (batch 4) up to 19.2 mm (batch 10)
and SPAN indexes between 1.6 (batch 9) and 4.6 (batch
8). After model simplification, with the elimination of
the quadratic and interaction terms, the obtained values
for the mean particle size (Y2) and for the SPAN value
(Y3) were fitted to linear models, according to the
following equations:
Mean particle size ðmmÞ ¼ 4:080:23PVAþ2:10PHBV
ð6Þ
SPAN ¼ 3:58 0:57PVAþ 0:10PHBV ð7Þ
The statistical analysis of the models indicates that
the concentration of the polymer in the organic phase is
the only factor that significantly influences the mean
particle size (p<0.05), with a positive effect.
This increase of particle size with the increase of
polymer concentration is well documented in the
literature (O’Donnell and McGinity 1997, Freitas
et al. 2005) and it can be explained by the increasing
viscosity of the organic phase and, as a consequence,
this phase will be more difficult to disperse into small
droplets. According to the fitted models, the concentra-
tion of the stabilizer has a statistical null effect on the
mean particle size (p>0.1) but has a significant
negative effect in the width of the particle size
distribution (p<0.01). The higher SPAN values were
observed for the formulations with 0.38% and 1% of
PVA concentration (batches 2, 6 and 8), which
correspond to the lower levels for this factor in the
experimental design. The obtained broader size dis-
tributions for these formulations are possible due to the
Figure 1. Response surface plot showing the effect of PHBV
concentration and PVA concentration on the encapsulation
efficiency of the flurbiprofen-loaded microspheres.
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microspheres aggregation during solvent evaporation,
caused by the low stabilizer concentration in the
aqueous phase. In fact, some degree of microspheres
aggregation was visible in these samples, in contrast to
all the other formulations, which yielded completely
free powders.
Surface morphology
Figure 2 shows the SEM micrographs of the surface
of PHBV blank microspheres (Figure 2(a)), flurbi-
profen-loaded microspheres (Figure 2(b)) and micro-
spheres after the in vitro release of flurbiprofen in a
saline solution (Figure 2(c)). Blank and drug-loaded
microspheres were spherical in shape with a very
rough surface. This morphology is typical of PHB
and PHBV microspheres and is attributed to the
highly crystalline character of these polymers
(Martin et al. 2000). Blank microspheres had a
compact structure with some visible surface pores
while drug-loaded microspheres presented large sur-
face cavities, probably derived from the collision
between the microspheres during hardening. It is also
possible to see fine drug particles coated on the
surface of the microspheres. After drug release,
microspheres presented a ‘washed’ aspect, with large
holes/pores on the surface and the crystalline polymer
morphology is again well visible.
Thermal analysis
Figure 3 reports the thermal behaviour of pure
flurbiprofen (Figure 3 (a)), of blank PHBV micro-
spheres (Figure 3(b)), a physical mixture of flurbiprofen
and blank PHBV microspheres (Figure 3(c)) and
flurbiprofen-loaded PHBV microspheres (Figure 3(d)).
Figure 3(a) displays a narrow endothermic peak at
115.4C, corresponding to the solid melting point.
Figure 3(b) shows two endothermic peaks of fusion
(145C and 164C) for the PHBV blank microspheres.
Double and multiple melting behaviour of PHB and
PHBV films obtained by solution casting have been
reported in the literature (Gunaratne and Shanks 2005)
and are attributed to the phenomenon of melting,
recrystallization and remelting during heating.
Figure 3(c) corresponds to the DSC profile obtained
from a physical mixture of flurbiprofen and blank
microspheres (25/75,%w/w) and combines the thermal
events previously described. Figure 3(d) illustrates the
thermal behaviour of flurbiprofen-loaded-PHBV
microspheres with 9.4% of experimental drug loading
(batch 1). The characteristic endothermic melting
peaks of the polymer are present but the endothermic
melting peak of flurbiprofen is not visible. Similar
results were also obtained for DSC studies of other
drug-loading polymeric particles prepared by solvent
evaporation methods (Freiberg and Zhu 2004).
According to Dubernet (1995), the disappearance
of the endothermic peak, correspondent to the
encapsulated drug melting point, indicates that the
drug is dissolved in the polymer as a solid solution
or that the drug is dispersed in the polymer in a
metastable molecular dispersion. This result is an
indication that the flurbiprofen particles that seem to
coat the surface of the drug-loaded microspheres in
SEM micrographs (Figure 2(b)) are probably in an
amorphous state, finely dispersed at the microspheres
surface.
In vitro drug release studies
The flurbiprofen release profiles from PHBV micro-
spheres, in a saline solution of pH 6 and at 37C,
were found to be very similar for all the prepared
batches, showing an initial burst release (of 15–25%
of total drug) in the first half hour and, after 8 h,
more than 90% of total drug was released. The time
required to release 50% of the encapsulated drug
(t50%) ranged between 105–155min for all the
formulations, with the exception of formulation 8,
which was 220min. Data analysis of t50% values
(Table II) showed that none of the investigated
factors had a significant effect on this variable
(p<0.01) and formulation 8 was identified as an
outlier by the implemented statistical analysis.
This means that the fitted model is a constant,
corresponding to the mean value of t50% of all
batches (128min). On the other hand, the dissolution
profile of the pure drug, alone or as a physical
mixture with blank microspheres, evidences a slower
release, with a t50% (255min) significantly (p<0.1)
higher than the mean t50% for the flurbiprofen-loaded
PHBV microspheres. This is illustrated in Figure 4,
where the in vitro release profiles from the drug-
loaded microspheres corresponding to the three
central points of the experimental design (2.5%
PVA, 3% PHBV) are compared with the dissolution
profile of the pure drug and of a physical mixture
of flurbiprofen and blank PHBV microspheres
(for clarity, the release profiles of the remaining
formulations of the experimental design are not
represented). In Figure 4 is also clear that the
percentage of released drug in the first 30min from
drug loaded microspheres is higher than the percen-
tage of the pure drug dissolved in the release medium
in the same time interval (10%). These results
indicate that the drug release from microspheres is
essentially controlled by the drug dissolution rate
rather than by the hydrolytic degradation of poly-
meric chains (as expected due to the known slow
degradation of PHB and PHBV) or by the diffusion
of the drug throughout the polymeric matrix that,
according to the SEM images, is a irregular and
porous structure, where the entrapped drug can easily
leach out by the dissolution medium. The dissolution
of poorly soluble water drugs, like flurbiprofen, is
affected by several physical properties, including
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crystal habit, particle size, polymorphism, surface
area and wettability (Zaghloul et al. 2001). In this
case, the higher dissolution rate of flurbiprofen from
PHBV microspheres, when compared to the dissolu-
tion rate profile of the pure drug, can be attributed to
the dispersion of the amorphous drug in the porous
matrix and surface of the microspheres, which
enhanced the contact with the dissolution medium,
leading to a faster dissolution.
Considering that the drug-to-polymer ratio was kept
constant in all formulations, in a ratio of 3:10,
and that this factor influences the in vitro drug
release profile of drug-loaded microspheres prepared
by the emulsification solvent evaporation method
Figure 2. SEM micrographs of: (a) blank microspheres; (b) flurbiprofen-loaded microspheres; (c) microspheres after drug
release.
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(Freiberg and Zhu 2004), in future studies the influence
of this factor will be investigated, with the objective of
obtaining flurbiprofen-PHBV loaded microspheres with
a more prolonged and sustained release profile.
Conclusions
In order to develop a particulate drug delivery system
using biodegradable and biocompatible polyesters
of biological origin, poly(3-hydroxybutyrate-co-3-
hydroxyvalerate), (PHB), microspheres of this
polymer, loaded with flurbiprofen, were successfully
prepared by an O/W emulsion solvent evaporation
method.
A response surface method was implemented to
understand the effect of polymer concentration and
stabilizer concentration in the microspheres final
properties. Results showed that encapsulation efficiency
was significantly affected by the two investigated
factors, with PVA concentration having a highly
negative effect, probably due to flurbiprofen’s solubility
enhancement in the aqueous phase in the presence of
higher amounts of stabilizer. Microspheres mean
particle size and size distribution were also affected by
the two investigated factors: increasing polymer con-
centration in the organic phase led to higher mean
particle sizes while the increase of surfactant concentra-
tion in the continuous phase narrowed the width of
particle size distribution. The time for the release of
50% of the encapsulated drug, t50%, was not signifi-
cantly influenced by any of the investigated factors.
The in vitro flurbiprofen release profiles from PHBV
microspheres were very similar for all the prepared
formulations, with more than 90% of the encapsulated
drug released in 8 h. Results indicated that drug
release was essentially controlled by the drug dissolu-
tion rate rather than by the hydrolytic degradation of
polymeric chains or by the drug diffusion throughout
the polymeric matrix. The observed higher dissolution
rate of flurbiprofen from PHBV microspheres, when
compared to the dissolution rate profile of the pure
drug, can be attributed to the dispersion of the
amorphous drug in the porous matrix and surface of
the microspheres.
These results demonstrate that it is possible to
control the quantity of drug loaded in the microspheres
and the characteristics of the particle size distribution
by changing the quantities of the two investigated
factors. On the other hand, the in vitro release profiles
of the flurbiprofen-loaded PHB microspheres were not
affected by these two factors. For this reason, other
factors, in particular the drug-to-polymer ratio, should
be investigated in order to control the characteristics of
the in vitro drug release profile of the prepared drug
delivery system.
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